Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The Fas/FasL pathway may play a role in alopecia areata.

This study observed that simvastatin promoted hair regrowth in a mouse model of alopecia areata by reducing inflammatory markers and T cell proliferation, partly through disruption of isoprenoid metabolite production.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

IL-27 may help prevent hair loss in alopecia areata by promoting immunosuppressive T cells.

This review discusses recent advances in understanding alopecia areata's disease mechanisms and highlights JAK molecules as promising therapeutic targets, but reports no new clinical results; controlled trials are needed.

In this study of C3H/HeJ mice, researchers observed that alopecia areata is associated with the expansion of exhausted-memory CD8 T cells in multiple organs, with autoreactive activation not fully explained by known mechanisms, shedding light on the immunological dynamics underlying the condition.

This pilot study suggests that lovastatin may counteract stress-induced MICA expression in hair follicles and enhance MICA shedding, potentially offering a complementary approach for alopecia areata treatment.

This research found that reduced expression of SIRT1 in human scalp tissue may contribute to alopecia areata development by inducing immune-inflammatory responses in hair follicle cells, suggesting that SIRT1 plays a regulatory role in hair follicle immunity.

This study analyzed blood samples from individuals with alopecia areata and found that NKG2D+ immune cells, particularly memory-like NK cells, may better correlate with disease activity compared to CD8+ cells, though significant variability among individuals complicates these findings.

This study found that transgenic mice overexpressing IKZF1 developed lesions similar to alopecia areata, suggesting that Ikaros may play a role in the disease's pathogenesis. Ikaros expression was also higher in human alopecia areata patients compared to controls.

BTNL2 helps protect hair follicles from immune attacks.

This article proposes that alopecia areata may be caused by immune attacks on hair follicles after an immune privilege collapse, suggesting new therapeutic approaches targeting this immune response pattern.

This study shows that IKZF1 and the protein IKAROS may play a role in the development of alopecia areata, based on findings from both mouse models and human scalp tissues.

This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.

This study reported that CCT oligodeoxynucleotide induced patchy hair loss in male mice with specific genetic traits, suggesting gender and genetic preferences in immune response.

This review discusses potential new drug treatment strategies for alopecia areata based on genome-wide association study findings, but it reports no new clinical results.

This study observed that Epigallocatechin-3-gallate (EGCG) can inhibit phosphorylation of STAT1 and reduce a specific subset of immune cells in vitro and ex vivo, suggesting a potential role in maintaining immune privilege in alopecia areata.

Specific immune cells cause alopecia areata and blocking certain proteins can prevent it.

In a mouse model of alopecia areata, this study found that IL-27 overexpression using an adeno-associated virus protected against disease development, potentially by promoting immunosuppressive T cells and reducing CD8 T cell infiltration into hair follicles.

Certain NK cell changes in blood may indicate alopecia areata progression.

In this study, blocking the CXCR3 receptor in mice prevented the development of alopecia areata by inhibiting the accumulation of specific T cells in the skin, suggesting a potential therapeutic approach for humans.

This study observed that in human scalp hair follicles, BTNL2 expression is lower in stressed conditions, which correlates with increased cytotoxic activity by gamma/delta and CD8+ T cells, suggesting a possible role for BTNL2 in controlling immune responses relevant to alopecia areata.

This study suggests that in alopecia areata, innate lymphoid cells type 1 may contribute to the disease’s pathogenesis by inducing hair follicle changes similarly to CD8+ T cells.

In this study, NKG2D polymorphism was not linked to increased susceptibility to systemic lupus erythematosus among Egyptian patients living in the Suez Canal area.

This study conducted a meta-analysis of gene expression data from alopecia areata patients, identifying 5109 differentially expressed genes and highlighting enriched pathways like JAK-STAT signaling, providing insights into the disease's pathogenesis and potential treatment targets.

This study suggests a connection between the unfolded protein response and upregulation of NKG2D ligands in stressed hair follicles, highlighting a potential role of PRDX5 in alopecia areata pathogenesis.

This review explores the expression of Perforin by gamma delta T cells in human skin and its role in cytotoxicity but reports no new experimental results.

This study identified somatostatin as a potential secretory factor contributing to the immune privilege of human hair follicles.

This study identified 14 genes affected by copy number variants that may contribute to alopecia areata, including four genes notably involved in autophagy and chromatin remodeling.

This study found distinct gene expression patterns in the blood of alopecia areata patients, suggesting involvement of immune processes and new pathways like Wnt signaling and apoptosis in disease pathogenesis.